Notice of initial substantial holder
Melbourne, Australia, 20 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read MoreChange of Director’s Interest Notice
Melbourne, Australia, 12 May 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreCLINUVEL progresses vitiligo study
CLINUVEL today announced that it will start treatment of vitiligo patients with...
Read MoreNotification regarding unquoted securities
Melbourne, Australia, 6 May 2022 ASX: XETRA-DAX: Level 1 ADR: CUV UR9...
Read MoreCEO letter
For the benefit of the 2.5% recently joined shareholders, I distinguish CLINUVEL’s...
Read MoreAppendix 4C & Activity Report
CLINUVEL PHARMACEUTICALS LTD today released its Appendix 4C – Quarterly Cashflow Report...
Read MoreNotice of ceasing to be a substantial holder
Melbourne, Australia, 27 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreInitial Director’s Interest Notice
Melbourne, Australia, 7 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreCLINUVEL appoints new Non-Executive Director
Melbourne, Australia, 04 April 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreChange of Director's Interest Notice
Melbourne, Australia, 23 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreChange of Director's Interest Notice
Melbourne, Australia, 02 March 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreCEO letter
On 24 February, the world plunged into instability, initiated by delusional warfare...
Read MoreCLINUVEL Reports Record December Half Year Operating Profit
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreAppendix 4D - ASX Listing Rule 4.2A.3 Half Yearly Report
Melbourne, Australia, 23 February 2022 ASX: XETRA-DAX: ADR Level 1: CUV UR9...
Read MoreFinancial Results Half Year Ended, 31 December 2021
CLINUVEL PHARMACEUTICALS LTD announced today the financial results for the half year...
Read More